Clene/CLNN

$0.33

-2.86%
-
1D1W1MYTD1YMAX

About Clene

Clene Inc. is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson's disease and multiple sclerosis. It specializes in the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its CNM-Au8 is an investigational first-in-class therapy that improves central nervous system cells' survival and function via a mechanism that targets mitochondrial function and the nicotinamide adenine dinucleotide pathway while reducing oxidative stress. Its CNM-ZnAg is a broad-spectrum antiviral, antibacterial agent comprised of zinc (Zn2+) and silver (Ag+) ions under development to treat infectious disease and to provide immune support for symptom resolution. Its CNM-AgZn17 is a gel polymer suspension of Zn2+ and Ag+ under development for treatment of infectious diseases and to support wound healing.

Ticker

CLNN

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Robert Etherington

Employees

82

Headquarters

Salt lake city, United States
Website
clene.com

Clene Metrics

BasicAdvanced
$39.81M
Market cap
-
P/E ratio
-$0.54
EPS
0.55
Beta
-
Dividend rate
$39.81M
0.55292
$1.09
$0.25
764.39K
1.534
1.532
53.413
199.268
-30.88%
-102.25%
-595.47%
-171.75%
60.877
2.973
2.973
38.27%
-15.51%
46.97%

What the Analysts think about Clene

Analyst Ratings

Majority rating from 5 analysts.
Buy

Price Targets

Average projection from 5 analysts.
1,415.15% upside
High $7.00
Low $1.00
$0.33
Current price
$5.00
Average price target

Clene Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-10,100% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$100K
0%
Net income
$-10.1M
320.83%
Profit margin
-10,100%
320.83%

Clene Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 17.24%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.15
-$0.29
-$0.02
-$0.06
-
Expected
-$0.15
-$0.12
-$0.09
-$0.07
-$0.08
Surprise
3.45%
136.05%
-77.78%
-17.24%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Clene stock?

Clene (CLNN) has a market cap of $39.81M as of April 19, 2024.

What is the P/E ratio for Clene stock?

The price to earnings (P/E) ratio for Clene (CLNN) stock is 0 as of April 19, 2024.

Does Clene stock pay dividends?

No, Clene (CLNN) stock does not pay dividends to its shareholders as of April 19, 2024.

When is the next Clene dividend payment date?

Clene (CLNN) stock does not pay dividends to its shareholders.

What is the beta indicator for Clene?

Clene (CLNN) has a beta rating of 0.55. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Clene stock price target?

The target price for Clene (CLNN) stock is $5, which is 1415.15% above the current price of $0.33. This is an average based on projections from 5 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Clene stock

Buy or sell Clene stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing